Key statistics
On Friday, Aligos Therapeutics Inc (ALGS:NAQ) closed at 7.32, 94.68% above the 52 week low of 3.76 set on Apr 11, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 6.70 |
|---|---|
| High | 7.47 |
| Low | 6.70 |
| Bid | 7.10 |
| Offer | 7.41 |
| Previous close | 6.49 |
| Average volume | 68.46k |
|---|---|
| Shares outstanding | 6.15m |
| Free float | 4.80m |
| P/E (TTM) | -- |
| Market cap | 39.94m USD |
| EPS (TTM) | -12.70 USD |
Data delayed at least 15 minutes, as of Feb 06 2026 21:00 GMT.
More ▼
- Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates
- Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer
- Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Aligos Therapeutics Presents Positive Data at HEP-DART 2025
- Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025
- Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results
- Aligos Therapeutics to Present at Upcoming Investor Conferences
- Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025
More ▼
